Conferences - Results from #1040

Viewing 1041-1060 of 11869 articles

ASCO GU 2024: PIVOT-006: A phase 3, Randomized Study of Cretostimogene Grenadenorepvec vs Observation for the Treatment of Intermediate Risk Non-muscle Invasive Bladder Cancer Following TURBT

ASCO GU 2024: A Phase II Study of Tislelizumab Monotherapy as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma

ASCO GU 2024: Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer in China: An Analysis of Unpublished Clinical Trial and Real-World Data

ASCO GU 2024: BCG Shortage: What’s on the Horizon to Replace?

ASCO GU 2024: Punch: Preliminary Results from a Phase II Study of Intra‑arterial Chemotherapy Combined with Tislelizumab and BCG in High-Risk Non-Muscle-Invasive Bladder Cancer

ASCO GU 2024: SAKK 06/19 - Intravesical Recombinant BCG Followed by Perioperative Chemo-Immunotherapy for Patients with Muscle-Invasive Bladder Cancer: A Multicenter, Single Arm Phase 2 Trial

ASCO GU 2024: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

ASCO GU 2024: Adverse Effects and Discontinuation of Pembrolizumab in BCG Refractory Non-Muscle Invasive Bladder Cancer

ASCO GU 2024: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Patient-Reported Outcomes in the Phase 3 JAVELIN Bladder 100 Trial

ASCO GU 2024: ABLE-41: Nadofaragene Firadenovec-Vncg Early Use and Outcomes in a Real-World Setting in the United States

ASCO GU 2024: Economic Burden of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the United States: Real-World Study

ASCO GU 2024: Urine-Based Testing for Patient Selection and Genomic Characterization of Patients with FGFR Alteration-Positive NMIBC Treated with TAR-210

ASCO GU 2024: Updated Results from AVENANCE: Real-World Effectiveness of Avelumab First-Line Maintenance in Patients with Advanced Urothelial Carcinoma and Analysis of Subsequent Treatment

ASCO GU 2024: Defining Molecular Features Associated with Microsatellite Instability and Response to Immune Checkpoint Blockade in Urothelial Carcinoma

ASCO GU 2024: FGFR3 Mutated Urothelial Carcinoma of Bladder or Upper Tract: A Comparative Genomic Landscape Study

ASCO GU 2024: Oral APL-1202 in Combination with Tislelizumab as Neoadjuvant Therapy in Patients with MIBC: Interim Analysis of ANTICIPATE Phase II Trial

ASCO GU 2024: Urachal and Non-urachal Adenocarcinomas of the Bladder: A Comparative Comprehensive Genomic Profiling Study

ASCO GU 2024: Predictive Value of Dynamic Changes in ctDNA and Baseline Biomarkers with Neoadjuvant Atezolizumab in Operable Urothelial Carcinoma in the ABACUS Trial

ASCO GU 2024: Safety and Efficacy of Enfortumab Vedotin in Patients with Metastatic/locally Advanced Urothelial Cancer: Real-World Evidence from a European Database

ASCO GU 2024: Optimizing Treatment Strategies for Patients with Positive Pelvic/Retroperitoneal Lymph Nodes – Complete Clinical Response: Now What?

48
49
50
51
52
53
54
55
56
57